CN1419917A - Oral pulse-invigorating liquid for treating chronic nephritis, and preparing method thereof - Google Patents
Oral pulse-invigorating liquid for treating chronic nephritis, and preparing method thereof Download PDFInfo
- Publication number
- CN1419917A CN1419917A CN 01129938 CN01129938A CN1419917A CN 1419917 A CN1419917 A CN 1419917A CN 01129938 CN01129938 CN 01129938 CN 01129938 A CN01129938 A CN 01129938A CN 1419917 A CN1419917 A CN 1419917A
- Authority
- CN
- China
- Prior art keywords
- chronic nephritis
- oral liquid
- radix
- oral
- tongmai koufuye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine in the form of oral liquid for curing chronic nephritis is disclosed. It has feature of high curative effect (93.75% of total effective rate).
Description
The present invention relates to treat the Chinese medicine oral liquid and the method for making thereof of chronic nephritis.
Chronic nephritis is a kind of commonly encountered diseases, and its course of disease is long, and protracted course of disease belongs to refractory disease.It is the one group of immune inflammation disease that is primary in glomerule that is caused by multiple reason, and Most patients all enters chronic renal failure sooner or later and needs dialysis treatment, is the main cause that present China causes chronic renal failure.Modern medicine adopts symptomatic treatments such as blood pressure lowering, anticoagulant, diuresis more, needleless medicine that pathogeny is treated still, and the advantage of therefore giving full play to Chinese medicine is imperative.In the last few years, the report of Chinese medicine primary disease was more, but or concentrate on certain disease of certain side treatment, or take the dosage form inconvenience, adopt oral decoction to cause the patient to be difficult to adhere to taking more; Or curative effect can't to assert and treat mechanism by experiment fuzzy; So all can influence therapeutic effect inevitably.
TONGMAI KOUFUYE of the present invention is to find in secular clinical practice, in the chronic nephritis evolution, Qi deficiency blood stasis type accounts for significant proportion, it is fallen ill by the deficiency of vital energy, the disease delay is difficult heals because of blood stasis causes, mainly fallen ill by immune disorder with the chronic nephritis of modern medicine, the pathogenesis that causes the disease progression deterioration because of blood coagulation disorders is extremely similar.Therefore,, find out effective proved recipe, make TONGMAI KOUFUYE according to clinical experience for many years.The prescription of TONGMAI KOUFUYE provided by the present invention is formed and is comprised: (weight content in the 30ml oral liquid):
Radix Astragali 10-30g, Radix Notoginseng 3-9g, Radix Angelicae Sinensis 12-15g, Radix Salviae Miltiorrhizae 12-15g
Most crucial recipe ingredient is (weight content in every 30ml oral liquid): Radix Astragali 10-30g, Radix Notoginseng 3-9g.
The dosage form of medicine provided by the present invention is an oral liquid formulations.
TONGMAI KOUFUYE is made up of medicines such as the Radix Astragali and Radix Notoginseng.Confirm that through modern pharmacological research the principal agent Radix Astragali has wide influence to the immune system of body, has stronger immunoregulation effect, show based on immunostimulant, but have immunosuppressive action under certain conditions again
[1,2,3]Radix Notoginseng studies confirm that and can not only make too high or too low immunoreation recover normal, has the effect of immunomodulator
[4]And can suppress platelet function, and promote fibrinolytic, blood viscosity is reduced, can significantly improve hypercoagulability in the body
[5]Zhang Shi etc. further study arasaponin, find that it can promote the interstitial cell apoptosis, and control Interstitial cell hyper-proliferative can delay the generation of glomerular sclerosis
[6]This shows that preventing and treating chronic nephritis with we has certain rationale.
In view of above etiology and pathogenesis, we select principal agent Radix Astragali QI invigorating, pseudo-ginseng blood-circulation-invigovating blood stasis dispelling, all medicines share prescription, strengthening vital QI to eliminate pathogenic factors, parum drug and centralize the power, directly establish, thereby regulate body's immunity, improve hemorheology and reach the purpose of preventing and treating chronic nephritis by benefiting QI for activating blood circulation at pathogeny.TONGMAI KOUFUYE method for making provided by the present invention comprises the steps:
The chopping of Chinese medicine raw material is milled → is decocted → precipitate with ethanol → dosing → filtration → sterilization → packing
Clinical research aspect: the strict MethodsThe cases enrolled of selecting.32 examples are organized in treatment, with the each 20ml of TONGMAI KOUFUYE, and every day 3 times; Matched group 30 examples are with JINSHUIBAO oral liquid 10ml (containing 4 of paecilomyces hepiall chens), every day 3 times.6 months courses of treatment.The result shows: the treatment group all is better than matched group (P＜0.05 or P＜0.01) improving clinical symptoms, reduce urine protein, regulate immunity of organism, improving aspects such as hemorheology is unusual.Treatment group total effective rate reaches 93.75%; Matched group is 60.0%; Two groups of total effective rates compare, and difference has significance meaning (P＜0.01).And find no any untoward reaction in this medicine use.
The experimentation aspect, on rat chronic nephritis model based, add " blood stasis due to qi deficiency " pattern type of having built, found that: TONGMAI KOUFUYE is measured the general state of rat model, biochemical indicator (comprising t lymphocyte subset group and hemorheology etc.) and nephridial tissue pathology all shows and improves significantly, especially improving aspect the kidney pathology, TONGMAI KOUFUYE can obviously alleviate the deposition of rat kidney mesangial region IgG, and significantly suppress the hypertrophy of mesangial cell and mesentery substrate, curative effect is better than the JINSHUIBAO matched group.
Animal acute toxicity test points out this medicine safety good, and its maximum tolerated dose is equivalent to 312 times of clinical application amount.
TONGMAI KOUFUYE provided by the present invention confirms through clinical experimental research: TONGMAI KOUFUYE is passed through benefiting QI for activating blood circulation, regulated body's immunity, improved high blood coagulation state, delayed the generation of glomerular sclerosis, thereby reach the purpose of improvement or stable renal function, so can be widely used in treating various kidney patients.
With this side (prescriptions such as the Radix Astragali, Radix Notoginseng, Radix Salviae Miltiorrhizae) treatment chronic nephritis Qi deficiency blood stasis type patient, the present domestic report that still do not have.The development of this medicine and use not only meet differentiation of tcm spirit, and evident in efficacy.Aspect the bonded Animal Model Making of chronic nephritis " disease-card ", also have certain innovation and advance in addition.
Now be widely used in other renal disease patients such as the nephritis patient in Guangdong Provincial TCM Hospital outpatient service and ward and diabetes, and promoted through the education doctor of all parts of the country, be applied to ground such as other provinces such as Guangxi, Yunnan and port, Australia, effect is satisfied.Through nearly 5 years clinical practice, strict clinical experimental research has proved that fully TONGMAI KOUFUYE is treatment chronic nephritis Qi deficiency blood stasis type patient's a active drug, and total effective rate reaches 93.75%.
Example 1
The TONGMAI KOUFUYE prescription of treatment chronic nephritis is formed: (weight content in the 30ml oral liquid):
Radix Astragali 15g, Radix Notoginseng 3g, Radix Angelicae Sinensis 6g, Radix Salviae Miltiorrhizae 6g.Example 2
The TONGMAI KOUFUYE prescription of treatment chronic nephritis is formed: (weight content in the 30ml oral liquid).
Radix Astragali 30g, Radix Notoginseng 6g, Radix Angelicae Sinensis 9g, Radix Salviae Miltiorrhizae 9g.Example 3
With decocting after the processing of the raw material of Chinese medicine in example 1 or the example 2 chopping, remove medicinal residues medicinal liquid is extracted with ethanol precipitation, extracting solution is carried out dosing, levelling pH value after-filtration, clear liquid is sent to sterilization, is distributed into product oral liquid at last.
Claims (5)
1. a TONGMAI KOUFUYE for the treatment of chronic nephritis is characterized in that, this oral liquid is formed with 30 milliliters of oral liquids, and middle weight content is represented to comprise:
Radix Astragali 10-30g, Radix Notoginseng 3-9g, Radix Angelicae Sinensis 12-15g, Radix Salviae Miltiorrhizae 12-15g.
2. according to the TONGMAI KOUFUYE of the treatment chronic nephritis described in the claim 1, it is characterized in that the composition of this oral liquid is represented to comprise with weight content in 30 milliliters of oral liquids:
Radix Astragali 10-30g, Radix Notoginseng 3-9g.
3. according to the TONGMAI KOUFUYE of the treatment chronic nephritis described in claim 1 or 2, it is characterized in that this oral liquid formulation is an oral liquid formulation.
4. the method for the TONGMAI KOUFUYE of the treatment chronic nephritis described in the preparation claim 1 or 2 is characterized in that method for making comprises the steps:
Prescription raw material of Chinese medicine processing → decoction → precipitate with ethanol → dosing → filter → sterilize → be distributed into product Chinese medicine oral liquid.
5, the TONGMAI KOUFUYE of treatment chronic nephritis according to claim 1 is characterized in that this oral liquid is widely used in various kidney patients, and meets all kinds of patients of blood stasis due to qi deficiency disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01129938 CN1419917A (en) | 2001-11-21 | 2001-11-21 | Oral pulse-invigorating liquid for treating chronic nephritis, and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 01129938 CN1419917A (en) | 2001-11-21 | 2001-11-21 | Oral pulse-invigorating liquid for treating chronic nephritis, and preparing method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1419917A true CN1419917A (en) | 2003-05-28 |
Family
ID=4669575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 01129938 Pending CN1419917A (en) | 2001-11-21 | 2001-11-21 | Oral pulse-invigorating liquid for treating chronic nephritis, and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1419917A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100453094C (en) * | 2006-03-22 | 2009-01-21 | 广州中医药大学第二临床医学院 | Medicine composition of effective parts for compound Tongmai Chinese medicine oral liquid and its preparing method |
| CN102949437A (en) * | 2012-11-28 | 2013-03-06 | 厦门大学附属第一医院 | Traditional Chinese medicine for treating diabetic retinopathy and preparation method thereof |
| CN107684611A (en) * | 2016-08-03 | 2018-02-13 | 刘玉宽 | It is a kind of to be used to treat Chinese medicine of ephritis, renal failure and preparation method thereof |
-
2001
- 2001-11-21 CN CN 01129938 patent/CN1419917A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100453094C (en) * | 2006-03-22 | 2009-01-21 | 广州中医药大学第二临床医学院 | Medicine composition of effective parts for compound Tongmai Chinese medicine oral liquid and its preparing method |
| CN102949437A (en) * | 2012-11-28 | 2013-03-06 | 厦门大学附属第一医院 | Traditional Chinese medicine for treating diabetic retinopathy and preparation method thereof |
| CN107684611A (en) * | 2016-08-03 | 2018-02-13 | 刘玉宽 | It is a kind of to be used to treat Chinese medicine of ephritis, renal failure and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102755594B (en) | Traditional Chinese medicine composition for treating acute and chronic hepatitis B and preparation method thereof | |
| CN102836339B (en) | Medicine for treating diabetic nephropathy | |
| CN1739611A (en) | Stasis relieving oral liquid for treating rhinitis and its prepn | |
| CN108853433A (en) | A kind of Chinese medicine and preparation method thereof for treating diabetic nephropathy | |
| CN105381132A (en) | Drug for treating thyroid nodule | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN102716276B (en) | Medicine for oral use for treating diabetes | |
| CN103977106B (en) | A kind of Chinese medicine preparation for the treatment of nephrotic syndrome and preparation method thereof | |
| CN101433586B (en) | Medicament for treating ischemic cerebrovascular disease and preparation method thereof | |
| CN106074810A (en) | A kind of three wonderful capsules and preparation method thereof | |
| CN102028897B (en) | Chinese patent drug for treating glomerular hematuria and preparation method thereof | |
| CN1419917A (en) | Oral pulse-invigorating liquid for treating chronic nephritis, and preparing method thereof | |
| CN101983689A (en) | Drug for treating prostatitis and preparation method thereof | |
| CN101732692B (en) | Compound Chinese medicament preparation capable of alleviating irregular menstruation and preparation method thereof | |
| CN102397363A (en) | Traditional Chinese medicine for treating hypertension | |
| CN1259961C (en) | Medicination for curing kidney disease and preparation method | |
| CN105902888A (en) | Traditional Chinese medicine decoction for treating infantile acute nephritis | |
| CN105770005A (en) | Preparation method for fresh portulaca oleracea and mulberry leaf low-temperature extract compound preparation for reducing blood sugar | |
| CN102247515B (en) | Traditional Chinese medicine compound preparation used for treating diabetic nephropathy, and preparation method thereof | |
| CN101502597B (en) | Medicament for treating stomachache and preparation method thereof | |
| CN100594925C (en) | Medicament for treating chronic kidney disease proteinuria and preparation thereof | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN1212147C (en) | Compound preparation of Chinese herbal medicine for treating chronic prostatitis and its preparing method | |
| CN105288410A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and application of traditional Chinese medicine composition | |
| CN103655771A (en) | Traditional Chinese medicine preparation for treating skin ulcers and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |